Test makers target monkeypox market as cases surge



By Natalie Grover

LONDON, June 3 (Reuters) - Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world's first major outbreak of the viral infection outside of Africa.

The scramble started last month, much like early 2020 when companies rushed to make kits to help diagnose COVID-19, creating a multibillion-dollar boon for test makers.

But demand for monkeypox tests will be a fraction of what it was for COVID, given monkeypox is not as transmissible nor as dangerous as COVID - it typically spreads through close contact and can cause flu-like symptoms and pus-filled skin lesions that usually resolve on their own within weeks.

And unlike the sudden emergence of COVID, there are vaccines, treatments and tests that can already help curb the spread of monkeypox.

A niche new market could soften - but won't make up for - the anticipated slowing of COVID diagnostic sales as the need to test for the SARS-CoV-2 virus ebbs and concern about monkeypox grows, analysts say.

Roche ROG.S , for instance, made 1.9 billion Swiss francs ($2.0 billion) in COVID test sales in the first quarter, and Barclays analyst Emily Field estimates the tests will generate 3 billion Swiss francs in total for the company in 2022.

"It would be very difficult for monkeypox revenues to offset this in any meaningful way," she said.

More than 550 confirmed cases of monkeypox have been reported by about 30 countries since early May. The majority were in Europe and not linked to travel to Africa, where the virus is endemic. Public health authorities suspect some degree of community transmission. No deaths have been reported.

Still, the World Health Organization (WHO) has said it expects infections to rise as surveillance expands and its Europe head warned the spread could accelerate as people gather for parties and festivals over the summer.

This outbreak is significant on the monkeypox scale, but there is not yet a need for hundreds of thousands of tests, which was the case when COVID emerged, said Daniel Bausch, senior director, emerging threats and global health security at FIND, the global alliance for diagnostics.

"This isn't going to be the next COVID ... so I don't think the needs are massive. I don't anticipate

supply to be an issue."

TESTING, TESTING

Some countries, including Switzerland and the Netherlands which have reported only a handful of cases, say that for now they have sufficient testing capacity for monkeypox. Britain, where nearly 200 cases have been confirmed, is working on expanding capacity.

Although researchers previously had fragmented access to the chemicals and other materials needed to conduct PCR tests for monkeypox, kits being developed by companies such as Roche theoretically allow them to have everything they need in one place to process a sample in a lab.

Kits like Roche's have not been cleared by regulators for use as a medical diagnostic – however, they are available for research purposes only.

Meanwhile, more than a dozen listed Chinese firms, including Jiangsu Bioperfectus Technologies 688399.SS , say they have added the European Union's CE mark of quality to their kits.

The regime allows test-makers to self-certify that they are complying with EU regulations, and can accordingly be sold in the region.

Broadly there are two types of test: PCR and antigen tests are designed to detect whether a person is currently or very recently infected, while antibody tests show whether a person has previously been infected.

The monkeypox virus is part of the orthopoxvirus family that also includes smallpox and cowpox

PCR tests are the gold standard test for the detection of monkeypox, according to the WHO, while the way antigen and antibody tests are designed makes it less likely that a positive result is definitively indicative of monkeypox.

It is unclear whether infected but symptomatic individuals can spread the virus, says the WHO, so it's not known if precautionary testing of suspected cases is needed.

However, since suspected cases are expected to isolate for up to 21 days, rapid antigen tests could be useful, given there are currently no pox virus diseases that have broadly spread across populations, said Carlos Maluquer de Motes, who runs a research group studying poxvirus biology at Surrey University.

Most diagnostic makers are focused on PCR tests for monkeypox. A few others, including Tetracore Inc, are working on rapid antigen tests.

However, caution is warranted.

"Virtually none of the kits, whether listed for research or otherwise, have gone through extensive validation," said Bausch. "It would be interesting to order all the tests that have suddenly come on the market and see what you get."

($1 = 0.9580 Swiss francs)



Disease experts call on WHO, governments for more action on
monkeypox

FACTBOX-Countries offering vaccine for monkeypox

EXPLAINER-What vaccines, treatments do we have to combat monkeypox?

EXPLAINER-How concerned should we be about monkeypox? FACTBOX-Monkeypox cases around the world



Reporting by Natalie Grover in London; additional reporting by Ludwig Burger in Frankfurt, Roxanne Liu in China, Michael Shields in Zurich and Anthony Deutsch in Amsterdam; Twitter: @NatalieGrover; Editing by Matt Scuffham, Josephine Mason and Mark Potter

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明